Literature DB >> 1802503

Visceral leishmaniasis mimicking a flare of systemic lupus erythematosus.

J Braun1, J Sieper, K L Schulte, E Thiel, K Janitschke.   

Abstract

Fever in systemic lupus erythematosus (SLE) may be caused by exacerbation of the disease itself or by infection. We report on a patient with a long standing history of SLE that was complicated by fever and pancytopenia with no splenomegaly. SLE disease activity was suspected because of an elevated DNA-antibody titer. The early positive response to corticoid therapy may have masked the underlying infection. Visceral leishmaniasis was diagnosed by a repeated bone marrow biopsy and serological testing.

Entities:  

Mesh:

Year:  1991        PMID: 1802503     DOI: 10.1007/BF02206670

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  7 in total

1.  Immunotherapy for parasitic disease.

Authors:  F A Neva
Journal:  N Engl J Med       Date:  1990-01-04       Impact factor: 91.245

2.  Visceral leishmaniasis in immunocompromised hosts.

Authors:  M L Fernández-Guerrero; J M Aguado; L Buzón; C Barros; C Montalbán; T Martín; E Bouza
Journal:  Am J Med       Date:  1987-12       Impact factor: 4.965

3.  Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease.

Authors:  J Cohen; A J Pinching; A J Rees; D K Peters
Journal:  Q J Med       Date:  1982

4.  New perspectives on a subclinical form of visceral leishmaniasis.

Authors:  R Badaro; T C Jones; E M Carvalho; D Sampaio; S G Reed; A Barral; R Teixeira; W D Johnson
Journal:  J Infect Dis       Date:  1986-12       Impact factor: 5.226

5.  Visceral leishmaniasis complicating systemic lupus erythematosus.

Authors:  P J Wallis; C J Clark
Journal:  Ann Rheum Dis       Date:  1983-04       Impact factor: 19.103

6.  Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated.

Authors:  E M Carvalho; O Bacellar; A Barral; R Badaro; W D Johnson
Journal:  J Clin Invest       Date:  1989-03       Impact factor: 14.808

7.  A comparison of three dosage regimens of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya.

Authors:  J D Chulay; S M Bhatt; R Muigai; M Ho; G Gachihi; J B Were; C Chunge; A D Bryceson
Journal:  J Infect Dis       Date:  1983-07       Impact factor: 5.226

  7 in total
  5 in total

1.  Visceral leishmaniasis, systemic lupus erythematosus and acute hepatitis.

Authors:  Annalisa Celant; Guido Chichino; Barbara Dal Bello; Marco Massarotti; Lorenzo Minoli; Bianca Marasini
Journal:  Rheumatol Int       Date:  2008-05-24       Impact factor: 2.631

2.  [History of the treatment of axial spondylarthritis with biologics-Part 1].

Authors:  J Braun; J Sieper
Journal:  Z Rheumatol       Date:  2022-09-05       Impact factor: 1.530

3.  [Pericardial tamponade revealing systemic lupus erythematosus during the course of atypical visceral leishmaniasis].

Authors:  Hajer Ben Brahim; Maha Ben Nasr; Hela Boussaid; Ikbel Kooli; Abir Aouam; Adnene Toumi; Chawki Loussaief; Mohamed Chakroun
Journal:  Pan Afr Med J       Date:  2014-08-21

4.  Visceral leishmaniasis or systemic lupus erythematosus flare?

Authors:  Sunny Garg; Mousumi Kundu; Amit Nandan Dhar Dwivedi; Lalit Prashant Meena; Neeraj Varyani; Asif Iqbal; Kamlakar Tripathi
Journal:  Case Reports Immunol       Date:  2012-08-22

5.  Visceral leishmaniasis in a patient with systemic lupus erythematosus.

Authors:  André Filipe Santos Silva; João Paulo Branco Calheiros Figueiredo Dias; João Miguel Neves Gonçalves Santos Nuak; Francisca Rocha Aguiar; José António Araújo Pinto; António Carlos Eugénio Megre Sarmento
Journal:  IDCases       Date:  2015-09-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.